The US Food and Drug Administration approved slightly fewer new drugs than in recent years, and the industry's focus on specialty-care products continued to shine through.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Changing R&D models in research-based pharmaceutical companies
Journal of Translational Medicine Open Access 27 April 2016
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Change history
08 February 2011
The company names of Cerexa and Sunovion were transposed in Table 1 and have been corrected online.
Rights and permissions
About this article
Cite this article
Mullard, A. 2010 FDA drug approvals. Nat Rev Drug Discov 10, 82–85 (2011). https://doi.org/10.1038/nrd3370
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd3370
This article is cited by
-
Antibacterial Alternatives to a Dying Antibiotic Pipeline
Current Treatment Options in Infectious Diseases (2023)
-
Changing R&D models in research-based pharmaceutical companies
Journal of Translational Medicine (2016)
-
Unraveling the autoimmune translational research process layer by layer
Nature Medicine (2012)
-
Personalized Medicine: A Personal View
Clinical Pharmacology & Therapeutics (2012)